Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To evaluate the comparative bioavailability between: • MK-5348 (vorapaxar) 0.2085 mg/mL oral suspension from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA; and • MK-5348 (Zontivity™) 2.08 mg tablet (equivalent to 2.5 mg vorapaxar sulfate) from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., USA; after a single-dose in healthy subjects under fasting conditions.
Critère d'inclusion
- Vorapaxar is indicated for the reduction of thrombotic cardiovascular
- events in patients with a history of myocardial infarction (MI) or with
- peripheral
- arterial disease (PAD)